Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
A boost in biosimilars sales provided only minor consolation to Biogen in 2020, as generic competition to its blockbuster Tecfidera (dimethyl fumarate) multiple sclerosis brand in the US late in the year took a bite out of the company’s annual sales, which fell by 6% to $13.4bn.
“Biosimilars delivered solid performance despite continued COVID-19 impact, with revenues of $796m for 2020 which represents 8% growth
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
